Therapeutic resistance to anti-oestrogen therapy in breast cancer.


Journal

Nature reviews. Cancer
ISSN: 1474-1768
Titre abrégé: Nat Rev Cancer
Pays: England
ID NLM: 101124168

Informations de publication

Date de publication:
10 2023
Historique:
accepted: 29 06 2023
medline: 27 9 2023
pubmed: 28 7 2023
entrez: 27 7 2023
Statut: ppublish

Résumé

The hormone receptor oestrogen receptor-α (ER) orchestrates physiological mammary gland development, breast carcinogenesis and the progression of breast tumours into lethal, treatment-refractory systemic disease. Selective antagonism of ER signalling has been one of the most successful therapeutic approaches in oncology, benefiting patients as both a cancer preventative measure and a cancer treatment strategy. However, resistance to anti-oestrogen therapy is a major clinical challenge. Over the past decade, we have gained an understanding of how breast cancers evolve under the pressure of anti-oestrogen therapy. This is best depicted by the case of oestrogen-independent mutations in the gene encoding ER (ESR1), which are virtually absent in primary breast cancer but highly prevalent (20-40%) in anti-oestrogen-treated metastatic disease. These and other findings highlight the 'evolvability' of ER

Identifiants

pubmed: 37500767
doi: 10.1038/s41568-023-00604-3
pii: 10.1038/s41568-023-00604-3
pmc: PMC10529099
mid: NIHMS1928016
doi:

Substances chimiques

Estrogens 0

Types de publication

Journal Article Review Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

673-685

Subventions

Organisme : NCI NIH HHS
ID : K12 CA184746
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States

Informations de copyright

© 2023. Springer Nature Limited.

Références

Endocr Relat Cancer. 2015 Oct;22(5):713-24
pubmed: 26162914
Nat Rev Clin Oncol. 2015 Oct;12(10):573-83
pubmed: 26122181
Nat Rev Cancer. 2017 Jan;17(1):54-64
pubmed: 27885264
ChemMedChem. 2020 Nov 18;15(22):2072-2097
pubmed: 32916035
Breast Cancer Res. 2014 Jan 22;16(1):R7
pubmed: 24451109
Science. 1995 Dec 1;270(5241):1491-4
pubmed: 7491495
Cell. 2019 Aug 8;178(4):949-963.e18
pubmed: 31353221
Mol Cell. 2007 Sep 7;27(5):691-700
pubmed: 17803935
Cancer Discov. 2022 Feb;12(2):356-371
pubmed: 34544752
J Steroid Biochem Mol Biol. 2009 Sep;116(3-5):187-90
pubmed: 19500671
Biochemistry. 1997 Dec 2;36(48):14897-905
pubmed: 9398213
Cancer Cell. 2018 Sep 10;34(3):427-438.e6
pubmed: 30205045
Clin Cancer Res. 2020 Nov 15;26(22):5974-5989
pubmed: 32723837
N Engl J Med. 2019 May 16;380(20):1929-1940
pubmed: 31091374
Cancer Cell. 2018 Dec 10;34(6):893-905.e8
pubmed: 30537512
Cancer Discov. 2018 Sep;8(9):1176-1193
pubmed: 29991605
Cancer Res. 2012 Jan 15;72(2):548-59
pubmed: 22108824
BMC Cancer. 2008 May 28;8:149
pubmed: 18507821
Virchows Arch. 2022 Jan;480(1):163-176
pubmed: 35029776
Nat Rev Drug Discov. 2022 Mar;21(3):181-200
pubmed: 35042991
Oncogene. 2021 Feb;40(5):997-1011
pubmed: 33323970
Oncogene. 2017 Apr 20;36(16):2255-2264
pubmed: 27748766
Science. 2022 Jan 14;375(6577):eabc1495
pubmed: 35025636
Cancers (Basel). 2021 Oct 17;13(20):
pubmed: 34680352
Cancers (Basel). 2022 Oct 24;14(21):
pubmed: 36358625
J Clin Oncol. 2020 Apr 20;38(12):1346-1366
pubmed: 31928404
Cancer Discov. 2015 Jan;5(1):72-81
pubmed: 25380844
Mod Pathol. 2010 Feb;23(2):205-12
pubmed: 19898421
Cell Rep. 2019 Mar 5;26(10):2667-2680.e7
pubmed: 30840889
Anticancer Drugs. 2015 Oct;26(9):948-56
pubmed: 26164151
Clin Cancer Res. 2004 Jan 1;10(1 Pt 2):331S-6S
pubmed: 14734488
Oncotarget. 2017 May 9;8(19):31347-31354
pubmed: 28430626
Oncogene. 2018 Aug;37(33):4581-4598
pubmed: 29748621
Mol Endocrinol. 2005 Jun;19(6):1543-54
pubmed: 15802375
Nat Commun. 2016 May 13;7:11579
pubmed: 27174596
Nat Genet. 2013 Dec;45(12):1446-51
pubmed: 24185510
Breast Care (Basel). 2020 Aug;15(4):347-354
pubmed: 32982644
J Clin Oncol. 2016 Sep 1;34(25):2961-8
pubmed: 27269946
Breast Cancer Res Treat. 1994;31(1):95-105
pubmed: 7981461
Cancer Res. 1988 Sep 15;48(18):5183-7
pubmed: 3409244
Nature. 2012 Oct 4;490(7418):61-70
pubmed: 23000897
Cell Rep. 2013 Sep 26;4(6):1116-30
pubmed: 24055055
Eur J Cancer. 2003 Aug;39(12):1684-9
pubmed: 12888362
NPJ Breast Cancer. 2018 Aug 2;4:22
pubmed: 30083595
J Steroid Biochem Mol Biol. 1990 Dec 20;37(6):771-5
pubmed: 2285589
Mol Cancer Res. 2016 Nov;14(11):1054-1067
pubmed: 27565181
Cancer Metastasis Rev. 2022 Dec;41(4):975-990
pubmed: 36229710
Sci Adv. 2022 Aug 26;8(34):eabm4358
pubmed: 36001652
Genes Dev. 2010 Oct 1;24(19):2219-27
pubmed: 20889718
Mol Cell Biol. 1993 Jun;13(6):3577-87
pubmed: 8497271
Sci Transl Med. 2015 Nov 11;7(313):313ra182
pubmed: 26560360
Clin Cancer Res. 2020 Dec 1;26(23):6149-6157
pubmed: 32988969
Semin Cancer Biol. 2022 Nov;86(Pt 2):14-27
pubmed: 36041672
Breast Cancer. 2006;13(1):74-83
pubmed: 16518065
Mol Cell Oncol. 2018 Oct 9;5(6):e1526005
pubmed: 30525098
Nat Genet. 2013 Dec;45(12):1439-45
pubmed: 24185512
CA Cancer J Clin. 2019 Nov;69(6):438-451
pubmed: 31577379
Breast. 2021 Aug;58:160-169
pubmed: 34087775
Cancer Treat Rev. 2022 Sep;109:102432
pubmed: 35839531
Cold Spring Harb Perspect Biol. 2010 Dec;2(12):a003178
pubmed: 20739412
Pharmacol Ther. 2018 Jun;186:1-24
pubmed: 29289555
Cold Spring Harb Perspect Med. 2017 Feb 1;7(2):
pubmed: 28003276
Front Immunol. 2019 Mar 01;10:348
pubmed: 30881360
Science. 2022 Sep 9;377(6611):1180-1191
pubmed: 35981096
J Natl Cancer Inst. 2003 Mar 5;95(5):353-61
pubmed: 12618500
Biochem Pharmacol. 2011 Jul 15;82(2):122-30
pubmed: 21501600
Ann Oncol. 2018 Jan 1;29(1):145-153
pubmed: 29045530
Cancer Res. 2001 May 1;61(9):3632-9
pubmed: 11325832
Endocrinology. 2001 Feb;142(2):838-46
pubmed: 11159857
Br J Cancer. 2004 Nov 1;91(9):1687-93
pubmed: 15477868
Nat Commun. 2017 Nov 30;8(1):1865
pubmed: 29192207
Sci Transl Med. 2022 Sep 21;14(663):eabo5959
pubmed: 36130016
Cancer Discov. 2020 Feb;10(2):198-213
pubmed: 31806627
J Med Chem. 1994 May 27;37(11):1550-2
pubmed: 8201587
Mol Cancer Ther. 2022 Jun 1;21(6):890-902
pubmed: 35642432
Oncogene. 2017 Apr 20;36(16):2286-2296
pubmed: 27748765
CA Cancer J Clin. 2022 Nov;72(6):524-541
pubmed: 36190501
Cancer Res. 2013 Dec 1;73(23):6856-64
pubmed: 24217577
Breast Cancer Res. 2017 May 23;19(1):60
pubmed: 28535794
Nat Rev Cancer. 2003 Nov;3(11):821-31
pubmed: 14668813
Nat Rev Clin Oncol. 2020 Jun;17(6):360-371
pubmed: 32152485
Nat Rev Cancer. 2018 Jun;18(6):377-388
pubmed: 29662238
Clin Cancer Res. 2014 Apr 1;20(7):1757-1767
pubmed: 24398047
Eur J Cancer. 2008 Jan;44(1):30-8
pubmed: 18068350
Ther Adv Med Oncol. 2022 Jul 30;14:17588359221113694
pubmed: 35923930
Breast Cancer Res Treat. 1988 Apr;11(1):37-43
pubmed: 3289634
Cancers (Basel). 2022 Feb 16;14(4):
pubmed: 35205742
Cancer Discov. 2017 Mar;7(3):277-287
pubmed: 27986707
J Natl Cancer Inst. 2006 Sep 20;98(18):1285-91
pubmed: 16985247
Mol Cell. 2005 May 13;18(4):413-24
pubmed: 15893725
Elife. 2016 Feb 02;5:
pubmed: 26836308
Sci Transl Med. 2017 Aug 9;9(402):
pubmed: 28794284
Cancer Res. 2017 Oct 15;77(20):5602-5613
pubmed: 28904064
Cancer Cell. 2020 Oct 12;38(4):534-550.e9
pubmed: 32888433
Cancer Res. 1997 Apr 1;57(7):1244-9
pubmed: 9102207
J Clin Oncol. 2000 Nov 15;18(22):3748-57
pubmed: 11078487
Ann Oncol. 2019 Jan 1;30(1):115-123
pubmed: 30423024
Endocr Relat Cancer. 2003 Jun;10(2):179-86
pubmed: 12790780
Future Oncol. 2019 Oct;15(28):3209-3218
pubmed: 31426673
J Clin Oncol. 2022 Aug 20;40(24):2789-2805
pubmed: 35839445
N Engl J Med. 2022 Jul 7;387(1):9-20
pubmed: 35665782
JAMA. 2019 Jan 22;321(3):288-300
pubmed: 30667505
Mol Cell Endocrinol. 2019 Aug 1;493:110452
pubmed: 31125586
Clin Cancer Res. 2003 Apr;9(4):1259-66
pubmed: 12684393
Cancer Res. 1994 May 15;54(10):2552-5
pubmed: 8168078
J Med Chem. 2021 Aug 26;64(16):11841-11856
pubmed: 34251202
Nature. 2019 Jul;571(7765):408-412
pubmed: 31243370
Endocrinology. 2003 Mar;144(3):1032-44
pubmed: 12586780
N Engl J Med. 2020 Dec 24;383(26):2557-2570
pubmed: 33369357
Oncogene. 2012 Jul 5;31(27):3223-34
pubmed: 22056872
Cancer. 2012 Oct 15;118(20):4929-35
pubmed: 22415862
Cancer Res. 2022 Apr 1;82(7):1321-1339
pubmed: 35078818
J Clin Oncol. 2008 Mar 1;26(7):1059-65
pubmed: 18227529
Mod Pathol. 2011 Jul;24(7):924-31
pubmed: 21552212
Sci Adv. 2016 Jun 24;2(6):e1501924
pubmed: 27386569
Biochim Biophys Acta Rev Cancer. 2019 Dec;1872(2):188315
pubmed: 31647985
Nat Med. 2021 Feb;27(2):310-320
pubmed: 33462444
Breast Cancer Res Treat. 1994;31(1):117-27
pubmed: 7981452
JAMA Oncol. 2016 Oct 01;2(10):1354-1360
pubmed: 27355489
Cancer Res. 2000 Dec 15;60(24):6890-4
pubmed: 11156387
J Clin Oncol. 2005 Apr 10;23(11):2469-76
pubmed: 15753463
Ther Adv Med Oncol. 2022 Mar 15;14:17588359221083956
pubmed: 35309087
Clin Cancer Res. 2017 Aug 15;23(16):4793-4804
pubmed: 28473534
Clin Cancer Res. 2019 Jan 1;25(1):277-289
pubmed: 30314968
J Pain Palliat Care Pharmacother. 2008;22(1):45-46
pubmed: 28792816
Mol Cancer Ther. 2021 Feb;20(2):250-262
pubmed: 33310762
J Clin Oncol. 2009 Sep 20;27(27):4530-5
pubmed: 19704066
Cancer Res. 2010 Mar 1;70(5):2085-94
pubmed: 20179196
Nat Cell Biol. 2001 Jan;3(1):15-23
pubmed: 11146621
J Biol Chem. 2006 Apr 7;281(14):9607-15
pubmed: 16459337
Cell Rep. 2018 Aug 7;24(6):1434-1444.e7
pubmed: 30089255
N Engl J Med. 2012 Feb 9;366(6):520-9
pubmed: 22149876
Clin Cancer Res. 2020 Feb 1;26(3):608-622
pubmed: 31591187
Nature. 2023 Jun;618(7963):144-150
pubmed: 37165196
JAMA Oncol. 2016 Oct 01;2(10):1310-1315
pubmed: 27532364
Clin Breast Cancer. 2022 Oct;22(7):642-649
pubmed: 35906130
Eur J Cancer Clin Oncol. 1983 May;19(5):615-21
pubmed: 6683633
Cancer Res. 1991 Aug 1;51(15):3867-73
pubmed: 1855205
Science. 2002 Mar 29;295(5564):2465-8
pubmed: 11923541
Mol Oncol. 2011 Feb;5(1):5-23
pubmed: 21147047
Cancers (Basel). 2022 Jan 09;14(2):
pubmed: 35053474
Lancet. 2011 Aug 27;378(9793):771-84
pubmed: 21802721
J Bone Miner Res. 1994 Aug;9(8):1251-8
pubmed: 7976507
Mol Cell Endocrinol. 2002 Jun 28;192(1-2):93-104
pubmed: 12088871
Ann Oncol. 2018 Apr 1;29(4):872-880
pubmed: 29360925
Genes Dev. 2006 Sep 15;20(18):2513-26
pubmed: 16980581
Endocr Relat Cancer. 2011 Aug 30;18(5):565-77
pubmed: 21734071
Nature. 2015 Jul 16;523(7560):313-7
pubmed: 26153859
Int J Mol Sci. 2021 Jul 22;22(15):
pubmed: 34360578
Explor Target Antitumor Ther. 2022;3(4):480-496
pubmed: 36071983
Ther Adv Med Oncol. 2018 Jul 17;10:1758835918786451
pubmed: 30038670
Nat Genet. 2019 Feb;51(2):207-216
pubmed: 30531871
PLoS One. 2018 Oct 10;13(10):e0204973
pubmed: 30304013
Int J Cancer. 2000 Mar 20;89(2):111-7
pubmed: 10754487
Expert Opin Investig Drugs. 2022 Jun;31(6):515-529
pubmed: 34694932

Auteurs

Marie Will (M)

Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Jackson Liang (J)

Department of Oncology Biomarker Development, Genentech, South San Francisco, CA, USA.

Ciara Metcalfe (C)

Department of Discovery Oncology, Genentech, South San Francisco, CA, USA. metcalfe.ciara@gene.com.

Sarat Chandarlapaty (S)

Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA. chandars@mskcc.org.
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. chandars@mskcc.org.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH